Letter to Editor "Possible protective effect of rosuvastatin in chemotherapy‑induced cardiotoxicity in HER2-positive breast cancer patients: a randomized controlled trial".
{"title":"Letter to Editor \"Possible protective effect of rosuvastatin in chemotherapy‑induced cardiotoxicity in HER2-positive breast cancer patients: a randomized controlled trial\".","authors":"Niher Tabassum Snigdha","doi":"10.1007/s12032-024-02520-4","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"41 11","pages":"281"},"PeriodicalIF":2.8000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-024-02520-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
期刊介绍:
Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.